2017
Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline
Risacher S, Anderson W, Charil A, Castelluccio P, Shcherbinin S, Saykin A, Schwarz A, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Morris J, Shaw L, Khachaturian Z, Sorensen G, Carrillo M, Kuller L, Raichle M, Paul S, Davies P, Fillit H, Hefti F, Holtzman D, Mesulam M, Potter W, Snyder P, Schwartz A, Montine T, Petersen R, Aisen P, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Jiminez G, Balasubramanian A, Mason J, Sim I, Beckett L, Harvey D, Donohue M, Jack C, Bernstein M, Fox N, Thompson P, Schuff N, DeCArli C, Borowski B, Gunter J, Senjem M, Vemuri P, Jones D, Kantarci K, Ward C, Jagust W, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Landau S, Morris J, Cairns N, Householder E, Taylor-Reinwald L, Shaw L, Trojanowki J, Lee V, Korecka M, Figurski M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Faber K, Kim S, Nho K, Thal L, National N, Albert M, Frank R, Hsiao J, Kaye J, Quinn J, Silbert L, Lind B, Carter R, Dolen S, Schneider L, Pawluczyk S, Beccera M, Teodoro L, Spann B, Brewer J, Vanderswag H, Fleisher A, Heidebrink J, Lord J, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Bell K, Ances B, Morris J, Carroll M, Creech M, Franklin E, Mintun M, Schneider S, Oliver A, Marson D, Griffith R, Clark D, Geldmacher D, Brockington J, Roberson E, Love M, Grossman H, Mitsis E, Shah R, deToledo-Morrell L, Duara R, Varon D, Greig M, Roberts P, Albert M, Onyike C, D’Agostino D, Kielb S, Galvin J, Cerbone B, Michel C, Pogorelec D, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy M, Petrella J, Borges-Neto S, Wong T, Coleman E, Arnold S, Karlawish J, Wolk D, Clark C, Smith C, Jicha G, Hardy P, Sinha P, Oates E, Conrad G, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Levey A, Lah J, Cellar J, Burns J, Swerdlow R, Brooks W, Apostolova L, Tingus K, Woo E, Silverman D, Lu P, Bartzokis G, Graff-Radford N, Parfitt F, Kendall T, Johnson H, Farlow M, Hake A, Matthews B, Brosch J, Herring S, Hunt C, van Dyck C, Carson R, MacAvoy M, Varma P, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Finger E, Pasternack S, Rachisky I, Trost D, Kertesz A, Bernick C, Munic D, Mesulam M, Lipowski K, Weintraub S, Bonakdarpour B, Kerwin D, Wu C, Johnson N, Sadowsky C, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Sirrel S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Allard J, Lerner A, Ogrocki P, Tatsuoka C, Fatica P, Fletcher E, Maillard P, Olichney J, DeCarli C, Carmichael O, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Burke A, Trncic N, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Adeli A, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Flashman L, Seltzer M, Hynes M, Santulli R, Sink K, Gordineer L, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Perry D, Mintzer J, Spicer K, Bachman D, Finger E, Pasternak S, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Smith K, Relkin N, Chaing G, Lin M, Ravdin L, Smith A, Raj B, Fargher K. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology 2017, 89: 2176-2186. PMID: 29070667, PMCID: PMC5696639, DOI: 10.1212/wnl.0000000000004670.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationDisease Assessment ScaleClinical declineAlzheimer's diseaseBaseline executive functionTau neuropathologyHippocampal volumeAD subtypesMRI scansAlzheimer's Disease Assessment ScaleClinical Dementia Rating SumF-fluorodeoxyglucose (FDG) PETBaseline clinical measuresFunctional Assessment QuestionnaireBaseline hippocampal volumeBaseline MRI scansAlzheimer's Disease Neuroimaging Initiative-1Amyloid-positive participantsVolumetric MRI scansExecutive functionAtrophy subtypesHippocampal atrophyClinical variablesCDR-SBADAS-CogIn vivo staging of regional amyloid deposition
Grothe M, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel S, Initiative F, Initiative A, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. In vivo staging of regional amyloid deposition. Neurology 2017, 89: 2031-2038. PMID: 29046362, PMCID: PMC5711511, DOI: 10.1212/wnl.0000000000004643.Peer-Reviewed Original ResearchConceptsAmyloid depositionAmyloid pathologyVivo stagingCognitive impairmentPrimary sensory-motor areasAmyloid stagesRegional amyloid depositionCSF Aβ42 levelsAlzheimer's disease dementiaSensory-motor areasAlzheimer's Disease Neuroimaging Initiative (ADNI) cohortNormal older individualsMedial temporal lobeMild cognitive impairmentAβ42 levelsDisease dementiaNeuropathologic observationsInitiative cohortAmyloid positivityTemporal lobeFull cohortCN individualsAssociative neocortexBrain regionsOlder individuals
2016
Accelerating rates of cognitive decline and imaging markers associated with &bgr;-amyloid pathology
Insel P, Mattsson N, Mackin R, Schöll M, Nosheny R, Tosun D, Donohue M, Aisen P, Jagust W, Weiner M, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts, CNA P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Graff-Radford, MBBCH N, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Elizabeth Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Ashok Raj B. Accelerating rates of cognitive decline and imaging markers associated with &bgr;-amyloid pathology. Neurology 2016, 86: 1887-1896. PMID: 27164667, PMCID: PMC4873684, DOI: 10.1212/wnl.0000000000002683.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmyloid beta-PeptidesAniline CompoundsAtrophyBiomarkersBrainCognitionCognitive DysfunctionDisease ProgressionEthylene GlycolsFemaleFluorodeoxyglucose F18HumansLongitudinal StudiesMagnetic Resonance ImagingMaleMental Status ScheduleNeuropsychological TestsPeptide FragmentsPositron-Emission TomographyRadiopharmaceuticalsRegression AnalysisConceptsMild cognitive impairmentFunctional declineNeuronal injuryCSF Aβ42Florbetapir PETAmyloid positivityRate of declineCognitive declineTemporal lobe atrophy ratesΒ-amyloid pathologyEarly Alzheimer's diseaseFluorodeoxyglucose PETAmyloid pathologyFDG-PETFuture trialsAtrophy ratesInclusion criteriaMixed-effects regressionΒ-amyloidCognitive impairmentAlzheimer's diseaseFirst signPatientsInjuryConsiderable proportion